针对慢性淋巴细胞白血病的免疫微环境:一个不断发展的治疗策略
1Houston Methodist West Hospital, Houston, USA.
European journal of haematology
|March 11, 2025
概括
新型免疫疗法在克服慢性淋巴细胞白血病 (CLL) 治疗耐药性方面表现有前途. 这些疗法针对瘤微环境和免疫失调,为复发性或耐药性CLL患者提供了更好的结果.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 慢性淋巴细胞白血病 (CLL) 治疗由于瘤异质性和微环境而面临阻力.
- 患有CLL的患者表现出免疫失调,影响T细胞功能.
- 针对细胞相互作用提供了一条改善免疫功能和治疗结果的途径.
研究的目的:
- 探索慢性淋巴细胞白血病 (CLL) 的新型免疫治疗策略.
- 针对CLL的治疗耐药性和免疫逃生机制.
- 评估免疫疗法改善临床结果和克服耐药性的潜力.
主要方法:
- 关于CLL中小分子抑制剂,免疫疗法和组合策略的当前文献的综述.
- 分析新兴疗法,包括双特异性抗体,CAR-T细胞疗法和三特异性抗体.
- 对复发性/耐药性CLL和高风险子组中新药的临床疗效数据的检查.
主要成果:
- 虽然免疫检查点抑制剂在CLL中反应有限,但它们在里希特转换中表现出有效性.
- 像epcoritamab这样的双特异性抗体在复发性/耐药性CLL中显示出初始疗效,包括高风险组.
- 新的策略,如三种特异性抗体和组合疗法正在调查中,以提高特异性和免疫激活.
结论:
- 免疫疗法有可能抵消免疫抑制性CLL微环境.
- 这些新的方法可以改善临床反应,降低感染风险,克服治疗耐药性.
- 新出现的证据支持免疫疗法作为治疗复发性或耐药性CLL的有希望的途径.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:17The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
01:27Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
01:27Cytotoxic T Cells-mediated Immune Response
825
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
825
01:21Cell-surface Signaling
51.4K
Hormones—or any molecule that binds to a receptor, known as a ligand—that are lipid-insoluble (water-soluble) are not able to diffuse across the cell membrane. In order to be able to affect a cell without entering it, these hormones bind to receptors on the cell membrane. When a first messenger, a hormone, binds to a receptor, a signal cascade is set off, causing second messengers, proteins inside the cell, to become activated, resulting in downstream effects.
51.4K